FierceBiotech Newshttp://www.fiercebiotech.com/feed
enEyeGate ekes out a tiny IPO to fund its R&D effortshttp://www.fiercebiotech.com/story/eyegate-ekes-out-tiny-ipo-fund-its-rd-efforts/2015-07-31?utm_medium=rss&utm_source=rss&utm_campaign=rss
<p>Massachusetts&#39; EyeGate Pharmaceuticals picked up $10 million in an IPO do-over, raising cash to support its sole clinical candidate.</p>
Biotech IPOsdrug deliveryEyegateocular diseasesR&DFri, 31 Jul 2015 15:19:24 +0000Damian Garde455036 at http://www.fiercebiotech.comGBT lines up for a $124M IPO with a pill for sickle cellhttp://www.fiercebiotech.com/story/gbt-lines-124m-ipo-pill-sickle-cell/2015-07-31?utm_medium=rss&utm_source=rss&utm_campaign=rss
<p>Global Blood Therapeutics, a graduate of Third Rock Ventures&#39; startup academy, set terms for an IPO worth as much as $124 million, looking to raise money for its oral sickle cell disease program.</p>
Global Blood TherapeuticsPipelineThird Rock VenturesFri, 31 Jul 2015 14:47:58 +0000Damian Garde455031 at http://www.fiercebiotech.comMerck's Ebola vaccine is 100% successful in interim Phase III resultshttp://www.fiercebiotech.com/story/mercks-ebola-vaccine-100-successful-interim-phase-iii-results/2015-07-31?utm_medium=rss&utm_source=rss&utm_campaign=rss
<p>Merck&#39;s Ebola vaccine, in development alongside NewLink Genetics, protected 100% of patients from contracting the virus in interim results from an ongoing study, giving rise to hopes it can help prevent future outbreaks.</p>
MerckNewLink GeneticsPipelineFri, 31 Jul 2015 13:40:33 +0000Damian Garde455026 at http://www.fiercebiotech.com125 ex-GSK R&D staffers in RTP face the ax--againhttp://www.fiercebiotech.com/story/125-ex-gsk-rd-staffers-rtp-face-ax-again/2015-07-31?utm_medium=rss&utm_source=rss&utm_campaign=rss
<p>Eight months after the ax dropped late last year, 125 former GlaxoSmithKline staffers in Research Triangle Park found their jobs back on the chopping block Thursday as their new employer at Parexel included them in a lineup of new layoffs.</p>
Chutes and LaddersGlaxoSmithKlineParexelFri, 31 Jul 2015 12:53:10 +0000John Carroll454996 at http://www.fiercebiotech.comAmgen lops another 6% off its R&D budget amid wide cost cutshttp://www.fiercebiotech.com/story/amgen-lops-another-10-its-rd-budget-amid-wide-cost-cuts/2015-07-31?utm_medium=rss&utm_source=rss&utm_campaign=rss
<p>Amgen, long criticized over its appetite for moonshot R&amp;D projects, scaled back its research budget by more than 10% in the second quarter, part of a companywide effort to cut costs while advancing a make-or-break pipeline.</p>
AmgenPipelineR&DFri, 31 Jul 2015 12:15:27 +0000Damian Garde454906 at http://www.fiercebiotech.comAegerion's embattled CEO Beer steps downhttp://www.fiercebiotech.com/story/aegerions-embattled-ceo-beer-steps-down/2015-07-31?utm_medium=rss&utm_source=rss&utm_campaign=rss
Chutes and LaddersFri, 31 Jul 2015 12:07:48 +0000Alok Saboo454901 at http://www.fiercebiotech.comAstraZeneca isn't giving up on brodalumab despite its links to suicidehttp://www.fiercebiotech.com/story/astrazeneca-isnt-giving-brodalumab-despite-its-links-suicide/2015-07-31?utm_medium=rss&utm_source=rss&utm_campaign=rss
<p>Amgen shocked the industry in May when it cut ties with an AstraZeneca-partnered psoriasis treatment after spotting alarming rates of suicidal thoughts among patients taking the antibody. But its former collaborator is remaining optimistic about the once-promising treatment, tentatively moving toward an FDA filing.</p>
AmgenAstraZenecabrodalumabPipelinepsoriasisR&DFri, 31 Jul 2015 11:35:22 +0000Damian Garde454896 at http://www.fiercebiotech.comRIP: AstraZeneca clips two pipeline programs in Q2http://www.fiercebiotech.com/story/rip-astrazeneca-clips-two-pipeline-programs-q2/2015-07-30?utm_medium=rss&utm_source=rss&utm_campaign=rss
Every quarter AstraZeneca notes at the end of its financial report which of its new drug programs are being discarded and dropped from the pipeline.Thu, 30 Jul 2015 15:39:37 +0000John Carroll454881 at http://www.fiercebiotech.comReport: Parexel layoffs include up to 200 ex-GlaxoSmithKline staffershttp://www.fiercebiotech.com/story/report-parexel-layoffs-include-200-ex-glaxosmithkline-staffers/2015-07-30?utm_medium=rss&utm_source=rss&utm_campaign=rss
<p>When GlaxoSmithKline reported last December that it was ripping into its R&amp;D operations in Research Triangle Park, NC, and laying off 900 staffers, the pharma giant softened the blow by noting that some 450 of the workers would be transferring to Parexel, a major CRO with close ties to Glaxo. But today many of those jobs appear to be in danger after all.</p>
GlaxoSmithKlineParexelThu, 30 Jul 2015 15:25:32 +0000John Carroll454861 at http://www.fiercebiotech.comFibroGen's anemia drug, not yet approved, is a hit among cheating cyclistshttp://www.fiercebiotech.com/story/fibrogens-anemia-drug-not-yet-approved-hit-among-cheating-cyclists/2015-07-30?utm_medium=rss&utm_source=rss&utm_campaign=rss
<p>FibroGen&#39;s in-development treatment for anemia is still in the midst of Phase III development, but thanks to a legal loophole, the pill has made its way into the world of competitive cycling, where its red blood cell-boosting effects can give athletes an advantage.</p>
FibroGenR&DThu, 30 Jul 2015 15:05:28 +0000Damian Garde454851 at http://www.fiercebiotech.com